When U.S. President Donald Trump recently floated the idea of imposing 200% tariffs on imported pharmaceuticals, headlines were quick to react—but for Canadian pharmacists, this is no time for passive concern. It’s time to prepare.
Though these tariffs are aimed primarily at India and China, where most generics and raw pharmaceutical ingredients originate, the ripple effects could hit Canada hard. In fact, Canada’s own exports—about $3 billion worth of generics annually to the U.S.—could become collateral damage, threatening our domestic drug supply, our pharmacy operations, and our patients’ access to affordable care.
(more…)